The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.
Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics’ Glaucoma Drug
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
